$TLRY

AI-powered systems are boosting cannabis yields 20% while improving compliance. Well-funded operators deploying cultivation automation gain significant competitive advantages.

Tilray trades cheaply in the fast-growing cannabis beverage sector, but persistent losses and weak fundamentals suggest it's a value trap, not a bargain.

Tilray stock surged then fell on marijuana rescheduling news. Schedule III change eases taxes but won't unlock U.S. market entry without full legalization.

Cannabis rescheduling offers hope but legalization remains years away. Tilray investors shouldn't bet on near-term U.S. market entry.

Roth Capital upgrades $TLRY to buy with $10 target, citing international growth and beverage strength. Skeptics note missed revenues and cannabis sector challenges.

Tilray acquires UK's Lyphe Group, stabilizes BrewDog, launches Hi*Ball Energy in UK, and files $180M equity program to fund global expansion amid potential U.S. cannabis rescheduling.

Tilray launches PORTAL, a premium cannabis brand featuring 95-99% THC products targeting experienced consumers in Canada ahead of 4/20.

Nike, Virgin Galactic, Tilray, and other companies report earnings during holiday-shortened week, with Nike under pressure from China demand weakness and tariffs.

Tilray posts record $217.5M quarterly revenue and narrows losses, but persistent negative cash flow and competitive headwinds keep investors wary.

Tilray completes BrewDog Australia acquisition with brewery and bars; stock falls 3.68% despite Asia-Pacific expansion strategy.

Altria's proven profitability and 6.1% dividend outshine Tilray's persistent losses and shareholder dilution in cannabis sector comparison.

Canadian securities settlements at major companies reveal stock declines, leadership changes, and restructuring far exceed announced legal payouts, exposing systematic disclosure vulnerabilities.

Tilray completes £33M BrewDog acquisition targeting $200M annual revenue boost, but stock falls 4.32% as investors question valuation and integration strategy.

Tilray acquires BrewDog assets for £33M in bid to boost annual beverage revenue to $500M, though stock falls 4.32% on announcement.

Tilray acquires BrewDog for £33M, creating ~$500M platform with projected $200M revenue and $6-8M EBITDA by 2027.

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

Tilray struggles with profitability despite diversification into hemp and beverages. Acquisition-driven growth caused shareholder dilution and asset write-downs, raising questions about long-term viability.

Tilray and Canopy Growth strengthen positions amid shifting U.S. cannabis regulations. Both improve financials, with Tilray offering broader geographic diversification versus Canopy's focused approach.

Cannabis market projected to grow from $2.24B in 2025 to $3.32B by 2030, driven by legalization, premium products, and innovation in consumption methods.

Global functional foods market reaching $438B by 2026 as companies innovate delivery formats like oral pouches and alternative caffeine platforms to meet consumer demand for convenience.